TTK Healthcare Limited Shares Surge 20% Ahead of Board Vote
Key highlights
- TTK Healthcare shares surged as much as 20% on November 17 after the board-meeting announcement.
- The board will consider a bonus NCRPS scheme on November 20, 2026.
- TTK Healthcare has not disclosed the NCRPS ratio, dividend rate, face value or redemption period.
- The trading window for designated persons is closed from November 16 to November 22, 2026.
powered by IRIS

TTK Healthcare Limited shares surged 20% on November 17 after the company said its board would consider a bonus issue of non-convertible redeemable preference shares on November 20, 2026. The proposed instrument would be issued to existing equity shareholders, but its ratio, dividend rate and redemption terms have not been disclosed.
Know TTK Healthcare inside out
Results, valuation, peers and who's buying, in one view.
Why did TTK Healthcare shares rise 20%?
TTK Healthcare shares rose as much as 20% in intraday trade after its November 16 regulatory filing brought a potential shareholder distribution into focus. The stock reportedly opened about 15% above its previous close at ₹1,067.65, reached ₹1,110.90 during the session and was later quoted around ₹1,052.60, up about 13.7%.
The trigger was not an approved issue but the scheduled board discussion. TTK Healthcare informed stock exchanges that directors would meet on Friday, November 20, to consider and approve a Scheme of Arrangement involving the issue of Non-Convertible Redeemable Preference Shares, or NCRPS, by way of bonus to equity shareholders.
The company made the disclosure under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing said the scheme would be considered under Section 230 and other applicable provisions of the Companies Act, 2013.
The market reaction reflected investor attention on a possible distribution to shareholders. However, the board meeting notice did not confirm that the scheme had been approved, implemented or allotted as of the date of the announcement.
What will the board consider on November 20?
TTK Healthcare's board is scheduled to consider and approve the proposed Scheme of Arrangement between the company and its equity shareholders on November 20, 2026. The stated purpose of the arrangement is the issuance of NCRPS by way of bonus to existing equity shareholders.
The company also closed its trading window for designated persons and their immediate relatives from November 16 through November 22, both dates inclusive. The closure was announced under the company's code of conduct in line with SEBI (Prohibition of Insider Trading) Regulations, 2015.
The board outcome is the immediate milestone for investors because it may provide the financial and operational terms that were absent from the initial notice. Any subsequent disclosures would clarify the proposed structure and the next steps in the arrangement.
What are non-convertible redeemable preference shares?
NCRPS are preference shares that cannot be converted into ordinary equity shares and are redeemable under terms set by the issuing company. They differ from a conventional equity bonus issue because they do not add to a holder's equity ownership in the company.
Preference shares can carry a fixed dividend entitlement and are generally redeemable after a specified period. But the exact economic value of any proposed TTK Healthcare issue cannot be assessed until the company discloses its dividend or coupon rate, redemption schedule and other conditions.
For existing equity holders, the proposed bonus format means the company is considering issuing an additional security rather than additional ordinary shares. The initial filing does not state whether the preference shares would be listed, nor does it state the source of funds for future redemption.
This distinction is important because the market price of the equity share does not by itself establish the value of the preference-share entitlement. The specific terms approved by the board would determine the rights attached to the proposed instrument.
Got a follow-up? Ask IRIS
Which terms has TTK Healthcare not disclosed yet?
TTK Healthcare has not disclosed the bonus entitlement ratio, face value, number of preference shares, dividend rate, redemption period or record date for the proposed NCRPS issue. These omissions mean shareholders do not yet know how many preference shares they may receive for each equity share held.
The company has also not provided the coupon or dividend structure, tenure, redemption date or other financial terms. Those details will be central to evaluating the proposed distribution because they define both the potential income entitlement and the timing of repayment.
The company completed the sale of its EVA and Good Home brands to Wipro Enterprises for ₹256 crore plus goods and services tax on September 4. Reports have identified the possible use of proceeds from that transaction as an area for investor attention, but TTK Healthcare's board-meeting notice does not link the proposed NCRPS issue to those proceeds.
TTK Healthcare's recent reported profit was also described as benefiting from the brand-sale gain, while underlying operating profitability remained weak. The notice on the proposed preference shares does not provide new guidance on operations, earnings or capital allocation beyond the proposed scheme.
What does the proposal mean for investors and the business?
For investors, the November 20 decision matters because it may establish whether the announced proposal becomes a defined corporate action and on what terms. Until the board provides the entitlement ratio and financial conditions, the 20% share-price reaction is tied to an announced proposal rather than a fully specified instrument.
The proposed NCRPS would not convert into equity and therefore would not dilute the existing equity ownership of shareholders. Reports noted that the structure would not increase ordinary equity ownership, including the 74.6% promoter stake cited in market commentary.
For TTK Healthcare, the proposal follows the completed sale of the EVA and Good Home brands. That transaction and the proposed distribution have placed attention on the company's capital structure and its remaining operating business, particularly because the available information does not provide a connection between the two events.
The broader healthcare and consumer-products market impact is limited to the disclosed corporate action. No change to TTK Healthcare's products, customers, employees or operating facilities was announced in the board-meeting notice.
Conclusion
TTK Healthcare's 20% share-price rise followed a board-meeting notice for a proposed bonus issue of non-convertible redeemable preference shares to equity holders. The announcement is significant because NCRPS would be a separate, redeemable security rather than additional equity shares, but the company has not yet disclosed the terms that would determine their value.
Investors should watch the November 20 board outcome for the bonus ratio, face value, dividend or coupon rate, redemption period, record date and any explanation of funding. TTK Healthcare has also not stated whether the proposed arrangement is connected to the ₹256 crore plus GST sale of its EVA and Good Home brands to Wipro Enterprises.


